Latest & greatest articles for prostate cancer screening

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer screening or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer screening and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer screening

81. Screening for prostate, breast and colorectal cancer in renal transplant recipients

Screening for prostate, breast and colorectal cancer in renal transplant recipients Screening for prostate, breast and colorectal cancer in renal transplant recipients Screening for prostate, breast and colorectal cancer in renal transplant recipients Kiberd B A, Keough-Ryan T, Clase C M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The paper examines the cost-effectiveness of specific screening for prostate, breast and colorectal cancer for patients who have received a renal transplant. Breast cancer screening comprised a mammogram every 18 months. Prostate cancer screening involved an annual digital rectal examination and a prostate specific antigen assay. The screening programme for colorectal cancer required a faecal

2003 NHS Economic Evaluation Database.

82. Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. (PubMed)

Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. In U.S. men, prostate cancer is the most common noncutaneous cancer and the second leading cause of cancer death. Screening for prostate cancer is controversial.To examine for the U.S. Preventive Services Task Force the evidence of benefits and harms of screening and earlier treatment.MEDLINE and the Cochrane Library, experts, and bibliographies of reviews.Researchers developed eight questions (...) representing a logical chain between screening and reduced mortality, along with eligibility criteria for admissible evidence for each question. Admissible evidence was obtained by searching the data sources.Two reviewers abstracted relevant information using standardized abstraction forms and graded article quality according to Task Force criteria.No conclusive direct evidence shows that screening reduces prostate cancer mortality. Some screening tests can detect prostate cancer at an earlier stage than

2002 Annals of Internal Medicine

83. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. (PubMed)

Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. To determine whether the more intensive screening and treatment for prostate cancer in the Seattle-Puget Sound area in 1987-90 led to lower mortality from prostate cancer than in Connecticut.Natural experiment comparing two fixed cohorts from 1987 to 1997.Seattle-Puget Sound and Connecticut surveillance, epidemiology, and end results (...) areas.Population based cohorts of male Medicare beneficiaries aged 65-79 drawn from the Seattle (n=94 900) and Connecticut (n=120 621) areas.Rates of screening for prostate cancer, treatment with radical prostatectomy and external beam radiotherapy, and prostate cancer specific mortality.The prostate specific antigen testing rate in Seattle was 5.39 (95% confidence interval 4.76 to 6.11) times that of Connecticut, and the prostate biopsy rate was 2.20 (1.81 to 2.68) times that of Connecticut during 1987-90

Full Text available with Trip Pro

2002 BMJ

84. Screening for prostate cancer

Screening for prostate cancer Screening for prostate cancer Screening for prostate cancer Harris R, Lohr K N, Beck R, Fink K, Godley P, Bunton A J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Harris R, Lohr K N, Beck R, Fink K, Godley P, Bunton A J. Screening for prostate cancer. Rockville: Agency for Healthcare Research and Quality (...) (AHRQ). Preventive Services Task Force Systematic Evidence Review No. 16. 2002 Authors' objectives To examine the evidence of the benefits and harms of screening and earlier treatment in reducing prostate cancer mortality and to assist the US Preventive Services Task Force in making recommendations on this topic. Authors' conclusions We are unable to determine the net benefit of screening because we cannot establish the presence and, if present, the magnitude of benefit from screening. We can

2002 Health Technology Assessment (HTA) Database.

85. Cost-benefit analysis of total, free/total, and complexed prostate-specific antigen for prostate cancer screening

Cost-benefit analysis of total, free/total, and complexed prostate-specific antigen for prostate cancer screening Cost-benefit analysis of total, free/total, and complexed prostate-specific antigen for prostate cancer screening Cost-benefit analysis of total, free/total, and complexed prostate-specific antigen for prostate cancer screening Ellison L, Cheli C D, Bright S, Veltri R W, Partin A W Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of prostate-specific antigen (PSA) for population-based prostate cancer screening. Five strategies were identified. These were total PSA (tPSA) 4.0 ng/mg, free PSA/tPSA (f/tPSA), and complexed PSA (cPSA) 3.8, 3.4, and 3.0 ng/mg. Type of intervention Screening. Economic study

2002 NHS Economic Evaluation Database.

86. A quantitative analysis of the costs and benefits of prostate cancer screening

A quantitative analysis of the costs and benefits of prostate cancer screening A quantitative analysis of the costs and benefits of prostate cancer screening A quantitative analysis of the costs and benefits of prostate cancer screening Benoit R M, Gronberg H, Naslund M J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed (...) critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the use of prostate specific antigen (PSA), either alone or in combination with digital rectal examination (DRE), in screening for prostate cancer. Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population The (model) study population comprised males aged between 50 and 70 years with at least a 10-year life expectancy, who had been screened using

Full Text available with Trip Pro

2001 NHS Economic Evaluation Database.

87. Screening for prostate cancer, Norwegian review of international studies

Screening for prostate cancer, Norwegian review of international studies Screening for prostate cancer, Norwegian review of international studies Screening for prostate cancer, Norwegian review of international studies Norwegian Knowledge Centre for the Health Services Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Norwegian Knowledge (...) Centre for the Health Services. Screening for prostate cancer, Norwegian review of international studies. Norwegian Knowledge Centre for the Health Services (NOKC). SMM-Report 3/1999. 1999 Authors' objectives To evaluate the available documentation on screening for prostate cancer, as summarised in the INAHTA report 'Prostate Cancer Screening. Evidence Synthesis and Update'. Authors' conclusions The group of experts agree with the main conclusion from the INAHTA report; routine screening

1999 Health Technology Assessment (HTA) Database.

88. Prostate cancer screening: evidence synthesis and update (INAHTA Joint Project)

Prostate cancer screening: evidence synthesis and update (INAHTA Joint Project) Deteccion precoz del cancer de prostata (projecto INAHTA) Prostate cancer screening: evidence synthesis and update (INAHTA Joint Project) Deteccion precoz del cancer de prostata (projecto INAHTA) Prostate cancer screening: evidence synthesis and update (INAHTA Joint Project) Schersten T, Baile M A, Asua J, Jonsson E Citation Schersten T, Baile M A, Asua J, Jonsson E. Deteccion precoz del cancer de prostata (projecto (...) INAHTA). Prostate cancer screening: evidence synthesis and update (INAHTA Joint Project) Vitoria Gasteiz: Basque Office for Health Technology Assessment (OSTEBA). D-99-03. 1999 Authors' objectives

To summarize scientific evidence regarding the effectiveness and cost-effectiveness of mass screening for prostate cancer.

Authors' conclusions Mass screening for prostate cancer is not recommended because of lack of evidence regarding the benefits and the considerable risks of adverse effects

1999 Health Technology Assessment (HTA) Database.

89. The diagnostic value of digital rectal examination in primary care screening for prostate cancer: a meta-analysis

The diagnostic value of digital rectal examination in primary care screening for prostate cancer: a meta-analysis The diagnostic value of digital rectal examination in primary care screening for prostate cancer: a meta-analysis The diagnostic value of digital rectal examination in primary care screening for prostate cancer: a meta-analysis Hoogendam A, Buntinx F, de Vet H C Authors' objectives To systematically review the literature in order to examine the diagnostic value of digital rectal (...) the studies, a narrative synthesis may have been more appropriate than statistical pooling. Nevertheless, the results appear to have been well pooled and the conclusions appear to be appropriate given the evidence. Implications of the review for practice and research Practice: The authors state that the DRE may have a place as an initial test when screening for prostate cancer. A negative result of DRE has a high predictive value. However, the moderate sensitivity should prevent the general practitioner

1999 DARE.

90. Economic evaluation of screening for prostate cancer: a randomized population based programme during a 10-year period in Sweden

Economic evaluation of screening for prostate cancer: a randomized population based programme during a 10-year period in Sweden Economic evaluation of screening for prostate cancer: a randomized population based programme during a 10-year period in Sweden Economic evaluation of screening for prostate cancer: a randomized population based programme during a 10-year period in Sweden Holmberg H, Carlsson P, Lofman O, Varenhorst E Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Three-yearly prostate cancer screening for men aged 50-69 years. The screening involved digital rectal examination (DRE) by specialists and general practitioners (GPs) in the first screening round, DRE by GPs in the second round, and prostate specific

1998 NHS Economic Evaluation Database.

91. Diagnosis, management and screening of early localised prostate cancer

Diagnosis, management and screening of early localised prostate cancer Diagnosis, management and screening of early localised prostate cancer Diagnosis, management and screening of early localised prostate cancer Selley S, Donovan J, Faulkner A, Coast J, Gillat D Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Selley S, Donovan J (...) , Faulkner A, Coast J, Gillat D. Diagnosis, management and screening of early localised prostate cancer. Health Technology Assessment 1997; 1(2): 1-96 Authors' objectives To summarise the available evidence on the diagnosis, management and screening of early localised prostate cancer. Authors' conclusions There is no justification for the introduction of population screening. PSA testing should be limited to men with clinical evidence of prostate cancer who have a life expectancy of more than 10 years

1997 Health Technology Assessment (HTA) Database.

92. Screening for prostate cancer (includes patient leaflet 'Information for men considering or asking for PSA tests')

Screening for prostate cancer (includes patient leaflet 'Information for men considering or asking for PSA tests') Screening for prostate cancer (includes patient leaflet 'Information for men considering or asking for PSA tests') Screening for prostate cancer (includes patient leaflet 'Information for men considering or asking for PSA tests') NHS Centre for Reviews and Dissemination Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA (...) . No evaluation of the quality of this assessment has been made for the HTA database. Citation NHS Centre for Reviews and Dissemination. Screening for prostate cancer (includes patient leaflet 'Information for men considering or asking for PSA tests') York: Centre for Reviews and Dissemination (CRD) 1997: 4 Authors' objectives To summarise the research evidence on screening for prostate cancer. Authors' conclusions There is increasing pressure on doctors to test men for the early detection of prostate cancer

1997 Health Technology Assessment (HTA) Database.

93. Diagnosis, management and screening of early localised prostate cancer

Diagnosis, management and screening of early localised prostate cancer Diagnosis, management and screening of early localised prostate cancer Diagnosis, management and screening of early localised prostate cancer Selley S, Donovan J, Faulkner A, Coast J, Gillatt D Authors' objectives To assess the clinical and cost-effectiveness of methods for the diagnosis, treatment and screening of early localised prostate cancer. Searching EMBASE, Cancerlit, MEDLINE, the Social Sciences Citation Index (...) studies. The studies included in this section of the review appear to have used needle biopsy as the reference standard. Participants included in the review No inclusion criteria relating to the characteristics of the participants were specified. The participants in the included studies were as follows. Diagnosis: males who were either volunteers or were referrals for suspected prostate cancer. Treatment: males with diagnosed prostate cancer. Screening: volunteers, attendees at clinics, and responders

1997 DARE.

94. Cost-effectiveness analysis of prostatic cancer screening

Cost-effectiveness analysis of prostatic cancer screening Cost-effectiveness analysis of prostatic cancer screening Cost-effectiveness analysis of prostatic cancer screening Nakagawa S, Ebisui K, Sugimoto K, Nakanishi H, Kanemitsu N, Watanabe H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. Health technology Standard tests in the screening of prostatic cancer (PC). Type of intervention Screening. Economic study type Cost-effective analysis. Study population A hypothetical cohort of 10,000 asymptomatic males for which estimations for PC screening were conducted for three age groups: 55-59, 60-69 and 70-79 years old. Setting Hospitals and clinics in Japan. Dates to which data relate The detection rate of PC, sensitivity and specificity of PC

1997 NHS Economic Evaluation Database.

95. Diagnosis, management and screening of early localised prostate cancer

Diagnosis, management and screening of early localised prostate cancer Diagnosis, management and screening of early localised prostate cancer: a review Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need

1997 NIHR HTA programme

96. Screening for cancer of the prostate: an evaluation of benefits, unwanted health effects and costs - nonsystematic review

Screening for cancer of the prostate: an evaluation of benefits, unwanted health effects and costs - nonsystematic review Screening for cancer of the prostate: an evaluation of benefits, unwanted health effects and costs - nonsystematic review Screening for cancer of the prostate: an evaluation of benefits, unwanted health effects and costs - nonsystematic review Hanley J A, McGregor M Record Status This is a bibliographic record of a published health technology assessment from a member (...) of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Hanley J A, McGregor M. Screening for cancer of the prostate: an evaluation of benefits, unwanted health effects and costs - nonsystematic review. Montreal: Conseil d'Evaluation des Technologies de la Sante du Quebec (CETS). 1995 Authors' objectives To evaluate the benefits, adverse health effects and costs of screening asymptomatic men for cancer of the prostate. Authors' conclusions From

1995 Health Technology Assessment (HTA) Database.

97. Costs and effectiveness of prostate cancer screening in elderly men

Costs and effectiveness of prostate cancer screening in elderly men Costs and effectiveness of prostate cancer screening in elderly men Costs and effectiveness of prostate cancer screening in elderly men Office of Technology Assessment Record Status This is a bibliographic record of a published health technology assessment. The agency responsible for the publication, formerly a member of INAHTA, has subsequently been disbanded. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation Office of Technology Assessment. Costs and effectiveness of prostate cancer screening in elderly men. Washington DC: U. S. Congress. Office of Technology Assessment (OTA) 1995: 130 Authors' objectives To examine the effectiveness, safety, and costs of screening for prostate cancer among asymptomatic men over 65 years in order to analyze the implications of a potential screening benefit under the U. S. Medicare program. Authors' conclusions Given the state of current

1995 Health Technology Assessment (HTA) Database.

98. Cost-effectiveness analysis in early detection of prostate cancer: an evaluation of six screening strategies in a randomly selected population of 2,400 men

Cost-effectiveness analysis in early detection of prostate cancer: an evaluation of six screening strategies in a randomly selected population of 2,400 men Cost-effectiveness analysis in early detection of prostate cancer: an evaluation of six screening strategies in a randomly selected population of 2,400 men Cost-effectiveness analysis in early detection of prostate cancer: an evaluation of six screening strategies in a randomly selected population of 2,400 men Gustafsson O, Carlsson P (...) , Norming U, Nyman C R, Svensson H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The early detection of prostate cancer: a cost-effectiveness analysis of six screening strategies using different combinations of digital rectal

1995 NHS Economic Evaluation Database.

99. Prostate cancer screening in a large corporation population

Prostate cancer screening in a large corporation population Prostate cancer screening in a large corporation population Prostate cancer screening in a large corporation population Kantrowitz W, Doyle J, Semeraro J, Krane R J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability (...) of the study and the conclusions drawn. Health technology Prostate cancer screening. Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population Male employees of the Polaroid Corporation aged between 50 and 65 years. Setting Occupational. A large public corporation medical department in the United States. Dates to which data relate The start date of the screening programme was unclear. Resources used and costs were presented for the actual programme. The price year

1995 NHS Economic Evaluation Database.

100. Screening for prostate cancer: a decision analytic view

Screening for prostate cancer: a decision analytic view Screening for prostate cancer: a decision analytic view Screening for prostate cancer: a decision analytic view Krahn M D, Mahoney J E, Eckman M H, Trachtenberg J, Pauker S G, Detsky A S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. Health technology Screening for prostate cancer with prostate-specific antigen (PSA), transrectal ultrasound (TRUS) and digital rectal examination (DRE). Type of intervention Screening/secondary prevention. Economic study type Cost-utility analysis. Study population Cohorts of men between the ages of 50 and 70. Setting Medical centre. The economic study was carried out in Ontario (Canada). Dates to which data relate Dates for effectiveness and resource

1994 NHS Economic Evaluation Database.